BOTTOM LINE UPFRONT
GenAI delivers meaningful value in healthcare RCM when deployed on top of clean data, standardized workflows, and strong governance. The organizations seeing measurable impact – including 2.5x higher appeal throughput, faster coding review, and improved revenue capture – are sequencing automation correctly: stabilizing operations first, applying predictive models second, and using GenAI as the scaling layer last.
In healthcare RCM, Generative AI – GenAI – is the story right now. Every conference keynote, vendor pitch, and trade publication promises that large language models will “revolutionize” the revenue cycle. Some of those promises are real… most are premature.
The reality is that GenAI is a powerful augmentation layer that works best (or works, period) when it sits on top of clean data and standardized processes. In fact, dirty data is the number one barrier to successful AI implementation and scaling.
Which means what separates the wins from the cautionary tales is not the technology itself, but the discipline to sequence it correctly: stabilizing foundational operations first, then using GenAI to scale what’s already working.
Where and why GenAI fails
The cautionary tales follow the same script:
- Deploying GenAI on dirty data: If your denial categorization is inconsistent across sites, a GenAI model trained on that data will produce inconsistent appeals. Garbage in, garbage out.
- Skipping governance: GenAI models hallucinate. In a regulated environment, that’s a compliance risk.
- Treating GenAI as a standalone initiative: Organizations that deploy GenAI before fixing their denial taxonomy, standardizing workflows, and baselining throughput metrics consistently underperform. GenAI amplifies whatever operating model it sits on top of, including a broken one.
The through line across all three: sequence was skipped. And the cost is both a failed pilot and an organizational skepticism that makes the next attempt harder.
The 4-step sequence for real ROI
Right now, healthcare organizations want to boast AI-enabled RCM – so they move quickly. Which sounds good in theory, but doesn’t capture value when speed is prioritized over sequence. The organizations with real AI-enabled RCM move in order: stabilize with rules, sharpen with prediction, and only then scale with GenAI:
Step 1: Data readiness
Everything starts here. Denial categorization must be treated as a living process rather than a one-time mapping exercise, because two different payers can use the same CARC code in fundamentally different ways. One may represent an impactable denial worth appealing. The other may be purely administrative. Without clean, consistently monitored data, every layer above it inherits the inconsistency. In other words: GenAI does not fix bad data but amplifies it.
Step 2: Rules-based automation
Clean data enables rules-based automation to do its job: standardizing workflows, routing denials consistently, and creating the repeatable processes that the next two layers depend on. This is where most of the unglamorous work happens, and where most organizations want to skip ahead. The ones that do pay for it later.
Step 3: Predictive targeting
With clean data and standardized workflows in place, predictive models can do something GenAI cannot: tell you where to focus (i.e., which denials are worth appealing, which accounts are at risk, or where human effort will have the most impact). This is what gives GenAI something meaningful to act on; without it, GenAI is generating output without direction.
Step 4: GenAI
Built on that foundation, GenAI takes the expertise of your best people and distributes it to every team member, every site, every shift.
When GenAI has something solid to build on, the results are tangible: organizations with mature automation foundations are seeing appeal throughput per FTE increase 2.5x, coder review time drop by 30-50% on routine encounters, and millions in missed charges surfaced within 90 days of deployment. GenAI is also unlocking value in RCM areas that were previously hard to scale: payer contracts run hundreds of pages, and GenAI tools that extract, cross-reference, and surface relevant policy language give teams faster access to what they need for appeals, underpayment identification, and contract negotiation – a capability that becomes especially critical in acquisition models where contract management is disjointed or documentation is scattered.
But the GenAI step also requires governance the earlier steps don’t: close human-in-the-loop review, audit trails, and clear escalation protocols. Define who is accountable when the model is wrong before you deploy, not after.
The bottom line
GenAI is not the revolution. It is the scaling layer, and it only works when built on a foundation of clean data and standardized processes. Before you deploy, ask yourself: is the process standardized? Is the data reliable? Can you govern the output? The organizations capturing real value are the ones that answered those questions first.